Press Release FeedGet the RSS feed
Menu

Business Wire

Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research

AstraZeneca

Announced at ESMO 2026: $200,000 in matched funding to advance the future of Canadian breast cancer survivorship.

TORONTO, October 27, 2026--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Canadians living with and beyond the disease. Announced at Breast Cancer Canada's Canadian Night reception during the European Society for Medical Oncology (ESMO) Congress in Madrid, the funding will support two Canadian research initiatives, each receiving $100,000 to advance innovative approaches to patient navigation, survivorship research and personalized care.

Through this partnership, Breast Cancer Canada and AstraZeneca Canada are advancing research and innovation to address critical gaps across the survivorship continuum. The funded projects will explore digital health and artificial intelligence (AI) approaches to strengthen patient navigation, better understand patient needs, and inform more coordinated, personalized care.

The announcement comes as survey data from Breast Cancer Canada highlights public support for better survivorship care:

  • 92% of Canadians agree the cancer journey does not end when active treatment concludes.

  • 83% support medically supervised survivorship plans to guide patients through long-term recovery.

"Finishing active treatment is a major milestone, but it is not the end of a patient's breast cancer journey," said Kimberly Carson, CEO of Breast Cancer Canada. "Patients can face ongoing side effects, uncertainty, and complex medical decisions for years. Through our partnership with AstraZeneca Canada, we are investing in responsible innovation to help ensure survivorship care advances alongside precision treatment."

"At AstraZeneca, we're driven by a bold ambition: to eliminate cancer as a cause of death, and that ambition extends beyond treatment to ensuring every survivor has access to the care and innovation they need to thrive," said Dave Finlay, Franchise Head, Breast Cancer at AstraZeneca Canada. "We are proud to partner with Breast Cancer Canada to support Dr. Kamal Haider and Dr. Amina Silva, whose research aims to improve care coordination, strengthen support and advance more personalized approaches to survivorship."

Breast Cancer Canada and AstraZeneca Canada Matched Research Grant Recipients

Patient Navigation After Treatment and Digital Health ($100,000)

Led by Dr. Kamal Haider, Medical Oncologist at the University of Saskatchewan, the SAGE-S project will explore and validate a two-way large language model to support survivorship, with research coordination across Saskatchewan, Alberta and British Columbia.

  1. FinanceAstraZeneca results: 9M and Q3 2026Companies: AstraZenecaContinued strong commercial performance and 12 positive Phase III programme readouts in the year to date CAMBRIDGE, England, October 30, 2026--AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER 1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,
  2. AIP&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain AwardsCompanies: Procter & GambleAstraZenecaNestléOMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestle, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results.
  3. AIP&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain AwardsCompanies: Procter & GambleAstraZenecaNestléAwards recognize supply chain innovation, long-term partnership, and community engagement at OMP conferences in Singapore and Shanghai ANTWERPEN, BE / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Si
  4. AIP&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain AwardsCompanies: Procter & GambleAstraZenecaNestléANTWERPEN, BELGIUM, Oct 22, 2026 - OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation. Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, planners can focus on the decisions that drive the business, and Nestlé continues to roll out best practices throughout the organization. Bekaert integrated scenario planning directly into its S&OP, shifting teams from reactive firefighting to proactive, value-driven conversations. In its green hydrogen business, what-if modeling protects mid- and long-term strategic control. Furthermore, planners use Unison Companion, OMP's generative AI assistant, to generate tables, compare scenarios, and retrieve information in natural language. "This award recognizes the ongoing transformation of our end-to-end supply chain planning," says Bo Yang, Senior Manager, Global Supply Chain Process Management at Bekaert Rubber Reinforcement. "We've moved from manual Excel calculations and individual experience to standardized planning on OMP's Unison Planning™ platform. Our decisions are now backed by data, and our planning accuracy has improved significantly." Long-Term Partnership Award: P&G and AstraZeneca P&G, with operations in approximately 70 countries, joins global biopharma leader AstraZeneca in accepting the award for proving that value compounds the longer the partnership runs. P&G celebrates 27 years of partnership with OMP dating back to 1999, and operates a planning network spanning more than 100 manufacturing sites and 200 distribution centers. The company has consolidated overlapping planning processes, with the majority of planning now handled touchlessly. "Receiving OMP's Long-Term Partnership Award reflects years of trust and teamwork between our teams," says Jen Aberilla, Director, Regional Supply Network Operations Planning at P&G. "We're proud of what we've achieved together and look forward to building on it." AstraZeneca has been working with OMP since 2021, replacing siloed, spreadsheet-based planning with a single capacity-constrained network plan. Most recently, the company has been collaborating with OMP on AI‑driven planning and advanced scenario modeling, allowing planners to focus on scenarios and exceptions. This has resulted in improved supply reliability and service levels, inventory reduction, and productivity savings. Community Engagement Award: Mars and ITC ITC's Paperboards & Specialty Papers Division, part of the Indian multi-business enterprise ITC Limited, and Mars, a global giant in confectionery, food products, and pet care services, received the Community Engagement Award for their active role in OMP Community events and councils. ITC was recognized for its commitment to openly sharing its planning transformation with the wider supply chain community. By presenting its experience to industry peers, ITC has given them a candid look at how its journey unfolds in practice, with lessons other planning teams can apply. Mars is a committed participant in the OMP Community councils and in governance through the executive board. Working with OMP, Mars has lowered inventory, consolidated its warehouse network, improved factory equipment effectiveness, and increased forecast accuracy. "The world's most demanding manufacturers plan with OMP, and it is a privilege to see those relationships deepen over 10, 20, and 27 years. The results they achieve through this community are concrete: inventory goes down, forecast accuracy goes up, and decisions happen faster. Congratulations to each of them!" says Philip Vervloesem, Chief Commercial and Markets Officer at OMP. About OMP OMP helps companies facing complex planning challenges to excel, grow and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper and packaging - benefit from using OMP's unique Unison Planning™. Solution and product inquiries Contact OMP +32 3 650 22 11 Media inquiries Kira Perdue (Carabiner) SOURCE: OMP
  5. AIGlobal Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZenecaCompanies: Johnson & JohnsonAstraZenecaPfizerRoche Holding"Life Science Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  6. AIOracleOracle e AstraZeneca collaborano per promuovere l'innovazione basata sull’AI in ambito sanitarioCompanies: Oracle CorporationAstraZenecaAustin, Texas and Abu Dhabi—Oct 20, 2026 Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, a